 CAMBRIDGE, Mass. SOUTH SAN FRANCISCO, Calif.--BUSINESS WIRE--Ultivue, Inc. and Fluidigm Corporation Nasdaq:FLDM today announced a co-marketing agreement in which the companies will offer customers a comprehensive portfolio of workflow solutions for biomarker discovery and drug development. Ultivue, a leader in advancing precision medicine solutions by accelerating tissue biomarker discovery and validation develops unique assays for use in multiplex immunofluorescence imaging and analysis. 